ArriVent BioPharma, Inc. (AVBP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

ArriVent BioPharma, Inc. (AVBP) closed at USD 16.79 on 2026-10-15, a change of -10.1 % over the past year, with a market capitalization of USD 821.47M.

ArriVent BioPharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ArriVent BioPharma, Inc. key figures

Previous close

USD 16.79 (2026-10-15)

1-year change

-10.1 %

Market cap

USD 821.47M

Enterprise value

USD 448.7M

P/E ratio (trailing)

-4.60

P/E ratio (forward)

-4.30

EPS (trailing)

-3.62

EPS (forward)

-3.87

PEG ratio

n/a

Price to book

2.19

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.52

Employees

77

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ArriVent BioPharma, Inc. and compare it with other stocks.